CytoPherx

CytoPherx is developing therapies to reduce mortality among patients with acute kidney failure due to a combination of acute kidney injury, sepsis, and/or multi-organ failure.

Recent CytoPherx News

CytoPherx Raises $34 Million Early Stage Venture Capital Round

Find Out More About ESP